Quality & complianceOfficial

Aprepitant Stada 80 mg capsules face Danish supply problems into March 2027

🇩🇰 DKMA · Thu 12 Nov 2026

The Danish Medicines Agency reports production problems at STADA Nordic ApS, with supply of the 80 mg hard capsules expected to be affected from early November 2026 to early March 2027.

The Danish Medicines Agency (DKMA) has published a supply notice for Aprepitant "Stada" 80 mg hard capsules, marketed in Denmark by STADA Nordic ApS. The notice, dated 12 November 2026, says there are current problems with supply of the product.

DKMA gives the expected period of disruption as the start of November 2026 to the start of March 2027, a window of roughly four months. The stated cause is production problems. The notice does not say what the problems are or where they arose.

The product is listed under the active substance aprepitant and ATC code A04AD12. The notice does not mention other strengths, other aprepitant products or alternative treatments, and it does not describe any measures to mitigate the shortage.

DKMA directs questions about the current status to the company itself. The notice appears in the agency's section on supply notifications for medicines, which sits under its shortage-of-medicines pages.

What it means for your team

  • Supply-chain and market-access teams in Denmark should check how the stated period, from early November 2026 to early March 2027, affects their stock and contracts.
  • The notice names no alternatives, so teams should contact STADA Nordic ApS for the current status, as DKMA advises.
  • Regulatory and quality staff should note that the stated cause is production problems, with no further detail given in the notice.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →